Mast Cells: The Key Players in Cardiac Remodelling
DOI:
https://doi.org/10.17140/PLMOJ-1-103Abstract
The Mast Cells (MCs) are part of the immune system and they are actively involved
in the inflammatory and allergic reactions. The MCs produce and release a wide variety of
biologically active products, eg, histamine, Tumor necrosis factor-α (TNF-α), Transforming
growth factor-β (TGF-β), interleukin and renin, which are involved in cardiac remodelling.
MCs are considered culprits in various cardiovascular pathologies such as pressure and volume
overload, ventricular dilatation, and heart failure. The deleterious role of MCs in failing heart
and myocardial remodelling is being rigorously pursued in animal and human studies. The focus
of this mini review is to highlight the detrimental effects of MCs in the cardiac remodelling
process
References
Ehrlich P. Contributions to the theory and practice of histological staining: Part I: The chemical conception of coloring; Part II: The aniline dyes in chemical, technological and histological relationship [dissertation] [in German]. Leipzig, Germany: Paul-Ehrlich-Institut; 1878: 65S.
Prussin C, Metcalfe DD. IgE, mast cells, basophils, and eosinophils. J Allergy Clin Immunol. 2006; 117: S450-S456. doi: 10.1016/j.jaci.2005.11.016
Weidner N, Austen KF. Heterogeneity of mast cells at multiple body sites. Fluorescent determination of avidin binding and immunofluorescent determination of chymase, tryptase, and carboxypeptidase content. Pathol Res Pract. 1993; 189: 156- 162. doi: 10.1016/S0344-0338(11)80086-5
Singh AP, Singh M, Balakumar P. Effect of mast cell stabilizers in hyperhomocysteinemia-induced cardiac hypertrophy in rats. J Cardiovasc Pharmacol. 2008; 51: 596-604. doi: 10.1097/ FJC.0b013e31817ae60f
Balakumar P, Singh AP, Ganti SS, Krishan P, Ramasamy S, Singh M. Resident cardiac mast cells: are they the major culprit in the pathogenesis of cardiac hypertrophy? Basic Clin Pharmacol Toxicol. 2008; 102: 5-9. doi: 10.1111/j.1742-7843.2007.00147.x
Dvorak AM. Ultrastructural studies of human basophils and mast cells. J Histochem Cytochem. 2005; 53: 1043-1070. doi: 10.1369/jhc.5R6647.2005
Mekori YA, Metcalfe DD. Mast cells in innate immunity. Immunol Rev. 2000; 173: 131-140. doi: 10.1034/j.1600- 065X.2000.917305.x
Cohn JN, Ferrari R, Sharpe N. Cardiac remodeling--concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling. J Am Coll Cardiol. 2000; 35: 569-582. doi: 10.1016/S0735-1097(99)00630-0
Balakumar P, Singh AP, Singh M. Rodent models of heart failure. J Pharmacol Toxicol Methods 2007; 56: 1-10. doi:
1016/j.vascn.2007.01.003 10. Levick SP, McLarty JL, Murray DB, Freeman RM, Carver WE, Brower GL. Cardiac mast cells mediate left ventricular fibrosis in the hypertensive rat heart. Hypertension 2009; 53: 1041-1047. doi: 10.1161/HYPERTENSIONAHA.108.123158
Mina Y, Rinkevich-Shop S, Konen E, et al. Mast cell inhibition attenuates myocardial damage, adverse remodeling, and dysfunction during fulminant myocarditis in the rat. J Cardiovasc Pharmacol Ther. 2013; 18: 152-161. doi: 10.1177/1074248412458975
Huang ZG, Jin Q, Fan M, et al. Myocardial remodeling in diabetic cardiomyopathy associated with cardiac mast cell activation. PLoS One. 2013; 8: e60827. doi: 10.1371/journal. pone.0060827
Levick SP, Gardner JD, Holland M, Hauer-Jensen M, Janicki JS, Brower GL. Protection from adverse myocardial remodeling secondary to chronic volume overload in mast cell deficient rats. J Mol Cell Cardiol. 2008; 45: 56-61. doi: 10.1016/j. yjmcc.2008.04.010
Sugden PH, Clerk A. “Stress-responsive” mitogen-activated protein kinases (c-Jun N-terminal kinases and p38 mitogen-activated protein kinases) in the myocardium. Circ Res. 1998; 83: 345-352. doi: 10.1161/01.RES.83.4.345
Shiota N, Rysä J, Kovanen PT, Ruskoaho H, Kokkonen JO, Lindstedt KA. A role for cardiac mast cells in the pathogenesis of hypertensive heart disease. J Hypertens. 2003; 21: 1935-1944.
Plenz G, Song ZF, Tjan TD, et al. Activation of the cardiac interleukin-6 system in advanced heart failure. Eur J Heart Fail. 2001; 3: 415-421. doi: 10.1016/S1388-9842(01)00137-4
Reid AC, Brazin JA, Morrey C, Silver RB, Levi R. Targeting cardiac mast cells: pharmacological modulation of the local renin-angiotensin system. Curr Pharm Des. 2011; 17: 3744- 3752. doi: 10.2174/138161211798357908
McLarty JL, Li J, Levick SP, Janicki JS. Estrogen modulates the influence of cardiac inflammatory cells on function of cardiac fibroblasts. J Inflamm Res. 2013; 6: 99-108. doi: 10.2147/JIR. S48422
Li J, Jubair S, Janicki JS. Estrogen inhibits mast cell chymase release to prevent pressure overload-induced adverse cardiac remodelling. Hypertension. 2015; 65: 328-334. doi: 10.1161/ HYPERTENSIONAHA.114.04238
Watkins SJ, Jonker L, Arthur HM. A direct interaction between TGF beta activated kinase 1 and the TGF beta type II receptor: implications for TGF beta signalling and cardiac hypertrophy. Cardiovasc Res. 2006; 69: 432-439. doi: 10.1016/j. cardiores.2005.11.007
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content published in Pathology and Laboratory Medicine (PLM) is licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows anyone to copy, distribute, transmit, and adapt the work — including for commercial purposes — provided appropriate credit is given to the original author(s) and source.
